FDA accepts AstraZeneca’s NDA for breast cancer combination therapy
2023-06-13
申请上市临床3期优先审批快速通道临床结果
Preview
来源: Pharmaceutical Technology
The combination of capivasertib and FASLODEX is intended to treat HR-positive, HER2-negative locally advanced or metastatic breast cancerHER2-negative locally advanced or metastatic breast cancer. Credit: vetpathologist / Shutterstock.com.
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s new drug application (NDA) for the combination of capivasertib and FASLODEX (fulvestrant), and granted it priority review.
The combination therapy is intended to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancerhuman epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in adult patients, after recurrence or progression on or after an endocrine-based regimen.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Enzalutamide in Breast Cancer GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Avapritinib in Breast Cancer GlobalData
View all
Capivasertib is an investigational oral therapy and a potent adenosine triphosphate (ATP)-competitive inhibitor of all three AKT [protein kinase B] isoforms (AKT1/2/3).
The regulator will announce its decision during the fourth quarter of 2023.
AstraZeneca stated that its NDA is being reviewed under Project Orbis.
AstraZeneca Oncology research and development executive vice-president Susan Galbraith stated: “This priority review decision underscores the potential of capivasertib to extend the effectiveness of endocrine-based treatment approaches for patients with HR-positive breast cancer who experience tumour progression on, or resistance to, these widely used therapies.
“We look forward to working with the FDA to bring this potential first-in-class AKT inhibitorAKT inhibitor to patients as quickly as possible.”
The submission of the NDA was based on the findings of the CAPItello-291 Phase III trial.
The randomised double-blind trial was designed to assess the efficacy of capivasertib along with FASLODEX against placebo plus FASLODEX.
The combination of capivasertib and FASLODEX showed a 40% reduction in disease progression risk or mortality in the overall trial population compared to placebo plus FASLODEX.
Earlier in 2023, the US FDA granted its fast track designation to capivasertib for the same indication.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。